Cardiovascular Diseases, Cardiovascular Morbidity, Covid19, Heart Failure, Myocardial Injury
Conditions
Keywords
Cardiovascular involvement, COVID-19
Brief summary
COVID-19 infection has been associated with numerous cardiac manifestations. Indeed, SARS-CoV-2 may impact on cardiovascular system through a direct myocardial infection or a secondary cardiac involvement due to hypoxia or metabolic supply-demand imbalance or prothrombotic inflammatory state. As a consequence of and besides acute myocardial damages, COVID-19 could also determine chronic cardiovascular consequences, with a significant impact on long-term prognosis, quality of life and functional capacity of COVID-19 survivors. On this basis, we aim to define the clinical and prognostic effects of myocardial involvement in COVID-19 patients.
Detailed description
COVID-19 infection has been associated with numerous cardiac manifestations. Indeed, SARS-CoV-2 may impact on cardiovascular system through a direct myocardial infection or a secondary cardiac involvement due to hypoxia or metabolic supply-demand imbalance or prothrombotic inflammatory state. As a consequence of and besides acute myocardial damages, COVID-19 could also determine chronic cardiovascular consequences, with a significant impact on long-term prognosis, quality of life and functional capacity of COVID-19 survivors. On this basis, we aim to define the clinical and prognostic effects of myocardial involvement in COVID-19 patients, with a 1-month and 6-month follow-up composed of clinical evaluation, electrocardiogram, trans-thoracic echocardiogram, cardiovascular magnetic resonance, chest computerized tomography scan and cardiopulmonary exercise test.
Interventions
None listed
Sponsors
Centro Cardiologico Monzino
IRCCS Policlinico S. Donato
Istituti Clinici Scientifici Maugeri SpA
Istituto Auxologico Italiano
Humanitas Hospital, Italy
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
patients who were hospitalized for COVID-19
Exclusion criteria
None.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cardiovascular mortality | 1 month | Mortality due to cardiovascular causes at 1 month after hospitalization |
| All-cause mortality | 1 month | Mortality due to all causes at 1 month after hospitalization |
| Major adverse cardiovascular events (myocardial infarction, cerebrovascular accident, hospitalizations due to heart failure, revascularizations, cardiovascular mortality) | 1 month | Major adverse cardiovascular events at 1 month after hospitalization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| NYHA class | 6 months | NYHA functional class: from I (no limitation of physical activity) to IV (severe limitation with symptoms at rest) |
| Left ventricular systolic function (cardiac magnetic resonance, echocardiography) | 6 months | Left ventricular systolic function evaluated with multimodality imaging |
Countries
Italy
Contacts
Primary ContactGiulio Stefanini, Prof.
Outcome results
None listed